Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA
Meanwhile, Novo Nordisk has submitted its oral semaglutide tablet (oral Wegovy) for weight-management indication, reporting ~15% weight loss in a ~64-68-week study
share from Novos GLP-1 medications
- Hair growth - hair growth has declined, most likely due to the lack of nutrients
Both GLP-1s and GIPs are tied to plenty of other compelling health benefits outside of weight loss, including diabetes management, reduced heart disease risk, and, potentially, dementia prevention
Obesity in 2010: the future of obesity medicine: where do we go from here